R-932348 choline
| Code | Size | Price |
|---|
| TAR-T28496-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28496-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28496-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
R-932348 choline, a dual JAK/SYK inhibitor, is used potentially for treatment of dry eye disease.
CAS:
1620142-65-5
Formula:
C28H36FN6O5S
Molecular Weight:
587.69
Purity:
0.98
SMILES:
C[N+](C)(C)CCO.CCC(O)=NS(=O)(=O)c1cc(Nc2ncc(F)c(Nc3ccc(OCC#C)cc3)n2)ccc1C
References
1. Velotta JB, Deuse T, Haddad M, Masuda E, Park G, Carroll D, Taylor V, Robbins RC, Schrepfer S. A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation. 2009 Mar 15;87(5):653-9. doi: 10.1097/TP.0b013e318196110f. PubMed PMID: 19295308.
2. Deuse T, Velotta JB, Hoyt G, Govaert JA, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier MP, Robbins RC, Schrepfer S. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation. 2008 Mar 27;85(6):885-92. doi: 10.1097/TP.0b013e318166acc4. PubMed PMID: 18360272.
3. Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014 Oct 13;26(4):479-94. doi: 10.1016/j.ccell.2014.08.017. PubMed PMID: 25284480; PubMed Central PMCID: PMC4198486.
4. Chang BY, Zhao F, He X, Ren H, Braselmann S, Taylor V, Wicks J, Payan DG, Grossbard EB, Pine PR, Bullard DC. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009 Aug 1;183(3):2183-92. doi: 10.4049/jimmunol.0804063. PubMed PMID: 19596999.